Premature vascular damage in systemic lupus erythematosus

References

• Tang S, Lui SL, Lai KN. Pathogenesis of lupus nephritis: An update. Nephrology (Carlton) 2005; 10(2)174–179
   PubMed Web of Science ®Google Scholar
• Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: The bimodal pattern revisited. Q J Med 1985; 55(216)87–98
   PubMedGoogle Scholar
• Haider YS, Roberts WC. Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 1981; 70(4)775–781
   PubMed Web of Science ®Google Scholar
• Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42(2)338–346
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jr, Jansen-McWilliams L, D' Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145(5)408–415
   PubMed Web of Science ®Google Scholar
• Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42(1)51–60
   PubMed Web of Science ®Google Scholar
• Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J, Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999; 26(11)2363–2368
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Sheldon E, McCune WJ, Kaplan MJ. Endothelial cell apoptosis in systemic lupus erythematosus: A common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103(10)3677–3683
   PubMed Web of Science ®Google Scholar
• Lima DS, Sato EI, Lima VC, Miranda F, Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29(2)292–297
   PubMed Web of Science ®Google Scholar
• Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget JE, Schwartz L, Sammaritano L, Levine DM, Salman JE. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 2007; 116(4)419–426
   PubMed Web of Science ®Google Scholar
• Valdivielso P, Gomez-Doblas JJ, Macias M, Haro-Liger M, Fernandez-Nebro A, Sanchez-Chaparro MA, Gonzalez-Santos P. Lupus-associated endothelial dysfunction, disease activity and arteriosclerosis. Clin Exp Rheumatol 2008; 26(5)827–833
   PubMed Web of Science ®Google Scholar
• Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46(1)194–199
   PubMed Web of Science ®Google Scholar
• Bruce IN, Burns RJ, Gladman DD, Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 2000; 27(10)2372–2377
   PubMed Web of Science ®Google Scholar
• Hosenpud JD, Montanaro A, Hart MV, Haines JE, Specht HD, Bennett RM, Kloster FE. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984; 77(2)286–292
   PubMed Web of Science ®Google Scholar
• Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000; 50(5)397–404
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MD, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25)2399–2406
   PubMed Web of Science ®Google Scholar
• Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007; 56(10)3412–3419
   PubMedGoogle Scholar
• Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25)2407–2415
   PubMed Web of Science ®Google Scholar
• Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ. Interferon-alpha promotes abnormal vasculogenesis in lupus: A potential pathway for premature atherosclerosis. Blood 2007; 110(8)2907–2915
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275(5302)964–967
   PubMed Web of Science ®Google Scholar
• Boyer M, Townsend LE, Vogel LM, Falk J, Reitz-Vick D, Trevor KT, Villalba M, Bendick PJ, Glover JL. Isolation of endothelial cells and their progenitor cells from human peripheral blood. J Vasc Surg 2000; 31(1 Pt 1)181–189
   PubMed Web of Science ®Google Scholar
• Bruno S, Bussolati B, Scacciatella P, Marra S, Sanavio F, Tarella C, and Camussi G. Combined administration of G-CSF and GM-CSF stimulates monocyte-derived pro-angiogenic cells in patients with acute myocardial infarction. Cytokine 2006.
   Google Scholar
• Bailey AS, Jiang S, Afentoulis M, Baumann CI, Schroeder DA, Olson SB, Wong MH, Fleming WH. Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells. Blood 2004; 103(1)13–19
   PubMed Web of Science ®Google Scholar
• Chinoy MR, Miller SA, Myers RL, Cilley RE, Dillon PW. Persistent vascular defects in lung allografts attributed to defective endogenous endothelial progenitors. J Surg Res 2005; 124(1)14–22
   PubMed Web of Science ®Google Scholar
• Choi JH, Hur J, Yoon CH, Kim JH, Lee CS, Youn SW, Oh IY, Skurk C, Murohara T, Park YB, Walsh K, Kim HS. Augmentation of therapeutic angiogenesis using genetically modified human endothelial progenitor cells with altered glycogen synthase kinase-3beta activity. J Biol Chem 2004; 279(47)49430–49438
   PubMed Web of Science ®Google Scholar
• Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001; 70(4)478–490
   PubMed Web of Science ®Google Scholar
• Moldovan L, Moldovan NI. Role of monocytes and macrophages in angiogenesis. EXS 2005, 94: 127–146
   PubMedGoogle Scholar
• Zhao Y, Glesne D, Huberman E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci USA 2003; 100(5)2426–2431
   PubMed Web of Science ®Google Scholar
• Zhang S, Jia Z, Ge J, Gong L, Ma Y, Li T, Guo J, Chen P, Hu Q, Zhang P, Liu Y, Li Z, Ma K, Li L, Zhou C. Purified human bone marrow multipotent mesenchymal stem cells regenerate infarcted myocardium in experimental rats. Cell Transplant 2005; 14(10)787–798
   PubMed Web of Science ®Google Scholar
• Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89(1)E1–E7
   PubMed Web of Science ®Google Scholar
• Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93(2)e17–e24
   PubMed Web of Science ®Google Scholar
• Loomans CJ, De Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, De Boer HC, Verhaar MC, Braam B, Rabelink TJ, Van Zonneveld AJ. Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004; 53(1)195–199
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353(10)999–1007
   PubMed Web of Science ®Google Scholar
• Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzinger W, Wolozcszuk W, Steiner G, Smolen JS. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005; 111(2)204–211
   PubMed Web of Science ®Google Scholar
• Awad O, Jiao C, Ma N, Dunnwald M, Schatteman GC. Obese diabetic mouse environment differentially affects primitive and monocytic endothelial cell progenitors. Stem Cells 2005; 23(4)575–583
   PubMed Web of Science ®Google Scholar
• Callaghan MJ, Ceradini DJ, Gurtner GC. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid Redox Signal 2005; 7(11–12)1476–1482
   PubMed Web of Science ®Google Scholar
• Chironi G, Walch L, Pernollet MG, Gariepy J, Levenson J, Rendu F, and Simon A. Decreased number of circulating CD34(+)KDR(+) cells in asymptomatic subjects with preclinical atherosclerosis. Atherosclerosis 2007;191:115–20
   Google Scholar
• Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Joen ES, Oh HY, Kim DK. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 2004; 24(7)1246–1252
   PubMed Web of Science ®Google Scholar
• Zhu JH, Chen JZ, Wang XX, Xie XD, Sun J, Zhang FR. Homocysteine accelerates senescence and reduces proliferation of endothelial progenitor cells. J Mol Cell Cardiol 2006; 40(5)648–652
   PubMed Web of Science ®Google Scholar
• Xu Q, Zhang Z, Davison F, Hu Y. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient mice. Circ Res 2003; 93(8)e76–e86
   Web of Science ®Google Scholar
• Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: Limitations for therapy?. Arterioscler Thromb Vasc Biol 2006; 26(2)257–266
   PubMed Web of Science ®Google Scholar
• Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92(24)11190–11194
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Vasa-Nicotera M. Aging of progenitor cells: Limitation for regenerative capacity?. J Am Coll Cardiol 2003; 42(12)2081–2082
   PubMed Web of Science ®Google Scholar
• Di Stefano R, Santoni T, Barsotti MC, Armani C, Chifenti B, Guida C, Vanacore R, Locci MT, Mariani M, Balbarini A. Different growth conditions for peripheral blood endothelial progenitors. Cardiovasc Radiat Med 2002; 3(3–4)172–175
   PubMedGoogle Scholar
• Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90(12)5002–5012
   PubMed Web of Science ®Google Scholar
• Grisar J, Steiner CW, Bonelli M, Karonitsch T, Schwarzinger I, Weigel G, Steiner G, Smolen JS. Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) 2008; 47(10)1476–1483
   PubMed Web of Science ®Google Scholar
• Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, Segal MS. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007; 56(11)3759–3769
   PubMedGoogle Scholar
• Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC. Haematopoietic and endothelial progenitor cells are deficient in quiescent Systemic Lupus Erythematosus. Ann Rheum Dis 2007;66:865–70.
   Google Scholar
• Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 1999; 18(14)3964–3972
   PubMed Web of Science ®Google Scholar
• Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11(9)3514–3522
   PubMed Web of Science ®Google Scholar
• Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci USA 2002; 99(18)11951–11956
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25(3)383–392
   PubMed Web of Science ®Google Scholar
• Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, Casanova JL. Inborn errors of interferon (IFN)-mediated immunity in humans: Insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008; 226: 29–40
   PubMed Web of Science ®Google Scholar
• Koyama S, Ishii KJ, Coban C, Akira S. Innate immune response to viral infection. Cytokine 2008; 43(3)336–341
   PubMed Web of Science ®Google Scholar
• Crow MK, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16(5)541–547
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52(5)1491–1503
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294(5546)1540–1543
   PubMed Web of Science ®Google Scholar
• Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, Bono M, Ferrantini M, Rozera C, Truini M, Belardelli F, Santi L, Noonan DM. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am J Pathol 2000; 156(4)1381–1393
   PubMed Web of Science ®Google Scholar
• Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5(10)2726–2734
   PubMed Web of Science ®Google Scholar
• Oliveira IC, Sciavolino PJ, Lee TH, Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA 1992; 89(19)9049–9053
   PubMed Web of Science ®Google Scholar
• Lara PN, Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin I, Galvin PH, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. SU5416 plus interferon alpha in advanced renal cell carcinoma: A phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003; 9(13)4772–4781
   PubMed Web of Science ®Google Scholar
• Leibovitch I, Loewenstein A, Alster Y, Rosenblatt I, Lazar M, Yassur Y, Rubinstein A. Interferon alpha-2a for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment. Ophthalmic Surg Lasers Imaging 2004; 35(1)16–22
   PubMedGoogle Scholar
• Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326(22)1456–1463
   PubMed Web of Science ®Google Scholar
• Kaban LB, Mulliken JB, Ezekowitz RA, Ebb D, Smith PS, Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999; 103(6 Pt 1)1145–1149
   PubMed Web of Science ®Google Scholar
• Aversa SM, Cattelan AM, Salvagno L, Crivellari G, Banna G, Trevenzoli M, Chiarion-Sileni V, Monfardini S. Treatments of AIDS-related Kaposi's sarcoma. Crit Rev Oncol Hematol 2005; 53(3)253–265
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983; 131(3)1300–1305
   PubMed Web of Science ®Google Scholar
• Wu WZ, Sun HC, Shen YF, Chen J, Wang L, Tang ZY, Iliakis G, Liu KD. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 2005; 131(3)169–178
   PubMed Web of Science ®Google Scholar
• Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: Regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004; 80(Suppl 1)85–93
   PubMedGoogle Scholar
• von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95(6)437–448
   PubMedGoogle Scholar
• Halaas O, Liabakk NB, Vik R, Beninati C, Henneke P, Sundan A, Espevik T. Monocytes stimulated with group B streptococci or interferons release tumour necrosis factor-related apoptosis-inducing ligand. Scand J Immunol 2004; 60(1–2)74–81
   PubMed Web of Science ®Google Scholar
• Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L, Cassatella MA. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004; 103(10)3837–3844
   PubMed Web of Science ®Google Scholar
• Lim R, Knight B, Patel K, McHutchison JG, Yeoh GC, Olynyk JK. Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology 2006; 43(5)1074–1083
   PubMed Web of Science ®Google Scholar
• Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114(23)2482–2489
   PubMed Web of Science ®Google Scholar
• Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007; 116(18)2043–2052
   PubMed Web of Science ®Google Scholar
• Levy Z, Rachmani R, Trestman S, Dvir A, Shaish A, Ravid M, Harats D. Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse model. Eur J Intern Med 2003; 14(8)479–483
   PubMedGoogle Scholar
• Pammer J, Reinisch C, Birner P, Pogoda K, Sturzl M, Tschachler E. Interferon-alpha prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation. Lab Invest 2006; 86(10)997–1007
   PubMed Web of Science ®Google Scholar
• Gerber SA, Pober JS. IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol 2008; 181(2)1052–1062
   PubMed Web of Science ®Google Scholar
• McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54(8)2541–2549
   PubMedGoogle Scholar
• Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, Sokka T, Raggi P, Pincus T, Stein CM. Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58(7)2105–2112
   PubMed Web of Science ®Google Scholar
• Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, Genin A, Van Dyke AL, Nackos E, Chander A, Gehrie E, Cron RQ, Whitehead AS. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54(7)2220–2227
   PubMedGoogle Scholar
• Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46(11)2957–2963
   PubMedGoogle Scholar
• de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfa E. Anti-lipoprotein lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus erythematosus?. Arthritis Rheum 2004; 50(11)3610–3615
   PubMedGoogle Scholar
• Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L, Antonini-Canterin F, Di Salvo G, De Gennaro Colonna V, La Carrubba S, Carerj S, and Turiel M. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009;8:281–6.
   Google Scholar
• Margutti P, Matarrese P, Conti F, Colasanti T, Delunardo F, Capozzi A, Garofalo T, Profumo E, Rigano R, Siracusano A, Alessandri C, Salvati B, Valesini G, Malorni W, Sorice M, Ortona E. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 2008; 111(9)4559–4570
   PubMed Web of Science ®Google Scholar
• Belizna CC, Richard V, Thuillez C, Levesque H, Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 2007; 7(1)46–51
   PubMed Web of Science ®Google Scholar
• Gresele P, Migliacci R, Vedovati MC, Ruffatti A, Becattini C, Facco M, Guglielmini G, Boscaro E, Mezzasaoma AM, Momi S, and Pengo V. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2008.
   Google Scholar
• Ansari A, Larson PH, Bates HD. Vascular manifestations of systemic lupus erythematosus. Angiology 1986; 37(6)423–432
   PubMed Web of Science ®Google Scholar
• Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment?. Am J Med 1986; 80(5)925–929
   PubMed Web of Science ®Google Scholar
• Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, Reveille JD. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66(9)1168–1172
   PubMed Web of Science ®Google Scholar
• Sachet JC, Borba EF, Bonfa E, Vinagre CG, Silva VM, Maranhao RC. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007; 16(4)273–278
   PubMed Web of Science ®Google Scholar
• Gibson WT, Hayden MR. Mycophenolate mofetil and atherosclerosis: Results of animal and human studies. Ann N Y Acad Sci 2007; 1110: 209–221
   PubMed Web of Science ®Google Scholar